Dr. Mark Robson on How DNA-Damaging Agents Function in Treating Breast Cancer
Mark Robson, MD, clinic director of the Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, talks about how DNA-damaging agents function in treating breast cancer.
Mark Robson, MD, clinic director of the Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, talks about how DNA-damaging agents function in treating breast cancer.
Robson says the idea behind the treatment is specifically to exploit a defect in a particular repair pathway; when double-stranded damage is done to the DNA. He says another option to make DNA-damaging agents work is to create damage abnormalities that require double strand repair pathways.
Robson adds that these agents stand in contrast to PARP inhibitors, which are still being investigated by researchers to determine how they function.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
